Small Vessel

VIRTUOSO® LUXE REPORT REVEALS TRAVELERS ARE SPREADING THEIR WINGS IN 2024

Retrieved on: 
火曜日, 11月 14, 2023
Motivation, Party, Virtuoso, Privacy, Small Vessel, City, Fear, Family, Knowledge, Travel, Luxé, Tourism, Nightclub, Antarctica

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- The 2024 Virtuoso® Luxe Report shows travelers are increasingly demonstrating a committed sense of adventure and urgency for experiences in far-flung locations.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- The 2024 Virtuoso® Luxe Report shows travelers are increasingly demonstrating a committed sense of adventure and urgency for experiences in far-flung locations.
  • Virtuoso is a respected trend forecaster, and the annual Luxe Report serves as a compass for determining consumer preferences in high-end luxury travel.
  • The Luxe Report identified five key trends upscale globetrotters are embracing in 2024.
  • Findings from the 2024 Virtuoso Luxe Report, including top countries and favorite cities, can be found here .

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Retrieved on: 
月曜日, 5月 1, 2023
Stent, Small Vessel, Investigational device exemption, Cardiac muscle, PTA, Restenosis, CAD, ISR, Revascularization, MACE, Trial of the century, PCI, Microangiopathy, Sirolimus, PMA, Patient, Physician, Risk, IDE, Coronary artery disease, FDA, SCB, Cutaneous small-vessel vasculitis, Drug-eluting stent, US FDA, Safety, Pharmaceutical industry, MD, TITAN

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.

Key Points: 
  • TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
  • US FDA, on the 25th of April 2023, granted the third IDE approval for Concept Medical's Sirolimus Coated Balloon – MagicTouch SCB.
  • Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the MagicTouch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA).
  • The current IDE approval will allow Concept Medical to initiate pivotal clinical study to support safety and effectiveness of the MagicTouch SCB in small vessel coronary disease.

Concept Medical received IDE approval to investigate safety and efficacy of its MagicTouch Sirolimus Coated Balloon Catheter for the treatment of small coronary artery disease

Retrieved on: 
月曜日, 5月 1, 2023
Stent, Small Vessel, Investigational device exemption, Cardiac muscle, PTA, Restenosis, CAD, ISR, Revascularization, MACE, Trial of the century, PCI, Microangiopathy, Sirolimus, PMA, Patient, Physician, Risk, IDE, Coronary artery disease, FDA, SCB, Cutaneous small-vessel vasculitis, Drug-eluting stent, US FDA, Safety, Pharmaceutical industry, MD, TITAN

TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.

Key Points: 
  • TAMPA, Fla., May 1, 2023 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's novel MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of Small Vessels (SV) in coronary arteries.
  • US FDA, on the 25th of April 2023, granted the third IDE approval for Concept Medical's Sirolimus Coated Balloon – MagicTouch SCB.
  • Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the MagicTouch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA).
  • The current IDE approval will allow Concept Medical to initiate pivotal clinical study to support safety and effectiveness of the MagicTouch SCB in small vessel coronary disease.